Agent · turn 1

I'll analyze case ICSR-001 systematically. Let me start by pulling the case details and the relevant drug label.

⚙ calls get_case(case_id=ICSR-001)

⚙ calls get_drug_label(drug_class=DLL3 T-cell engager (BiTE))

↳ get_case result

show data

{
  "case_id": "ICSR-001",
  "study_drug": "Tarlatamab",
  "drug_class": "DLL3 T-cell engager (BiTE)",
  "patient": {
    "age": 64,
    "sex": "M",
    "comorbidities": [
      "ES-SCLC, 2nd line",
      "former smoker"
    ],
    "concomitant_meds": [
      "dexamethasone premedication",
      "ondansetron"
    ]
  },
  "narrative": "64-year-old man with extensive-stage small cell lung cancer received his first step-up dose of the DLL3 T-cell engager. Approximately 8 hours after dosing he developed fever to 39.2C with rigors and low blood pressure (88/54) requiring IV fluids; this was graded as cytokine release syndrome. On day 2 nursing noted he was confused with a coarse tremor and a drop in his ICE score (neurotoxicity). He was admitted to hospital and treated with tocilizumab and steroids; symptoms resolved over 48 hours. He was re-dosed at the next cycle with premedication and had only mild recurrence. No infection was identified on workup.",
  "events": [
    "fever with low blood pressure (CRS)",
    "confusion with tremor (neurotoxicity)"
  ]
}

↳ get_drug_label result

show data

{
  "drug_class": "DLL3 T-cell engager (BiTE)",
  "examples": [
    "Tarlatamab"
  ],
  "labeled": [
    "Cytokine release syndrome",
    "Immune effector cell-associated neurotoxicity syndrome",
    "Pyrexia",
    "Neutropenia",
    "Anaemia",
    "Fatigue",
    "Hypotension"
  ],
  "boxed_warning": "Cytokine release syndrome and neurologic toxicity including ICANS.",
  "note": "CRS and ICANS are expected, very common, on-target effects of T-cell engagers; typically occur within days of the first/step-up doses."
}

Agent · turn 2

Now let me code the events to MedDRA PTs. The narrative describes several discrete clinical findings, so I'll look up each.

⚙ calls meddra_lookup(term=cytokine release syndrome)

⚙ calls meddra_lookup(term=fever)

⚙ calls meddra_lookup(term=low blood pressure)

⚙ calls meddra_lookup(term=rigors)

⚙ calls meddra_lookup(term=confusion)

⚙ calls meddra_lookup(term=tremor)

⚙ calls meddra_lookup(term=neurotoxicity)

↳ meddra_lookup result

show data

{
  "query": "cytokine release syndrome",
  "count": 1,
  "matches": [
    {
      "pt": "Cytokine release syndrome",
      "soc": "Immune system disorders",
      "synonyms": [
        "crs",
        "cytokine storm",
        "infusion cytokine reaction"
      ]
    }
  ]
}

↳ meddra_lookup result

show data

{
  "query": "fever",
  "count": 2,
  "matches": [
    {
      "pt": "Febrile neutropenia",
      "soc": "Blood and lymphatic system disorders",
      "synonyms": [
        "fever with low white count",
        "neutropenic fever"
      ]
    },
    {
      "pt": "Pyrexia",
      "soc": "General disorders and administration site conditions",
      "synonyms": [
        "fever",
        "high temperature",
        "febrile",
        "raised temperature"
      ]
    }
  ]
}

↳ meddra_lookup result

show data

{
  "query": "low blood pressure",
  "count": 1,
  "matches": [
    {
      "pt": "Hypotension",
      "soc": "Vascular disorders",
      "synonyms": [
        "low blood pressure",
        "low bp"
      ]
    }
  ]
}

↳ meddra_lookup result

show data

{
  "query": "rigors",
  "count": 0,
  "matches": []
}

↳ meddra_lookup result

show data

{
  "query": "confusion",
  "count": 1,
  "matches": [
    {
      "pt": "Immune effector cell-associated neurotoxicity syndrome",
      "soc": "Nervous system disorders",
      "synonyms": [
        "icans",
        "neurotoxicity",
        "neurologic toxicity",
        "confusion with tremor",
        "encephalopathy",
        "ice score drop"
      ]
    }
  ]
}

↳ meddra_lookup result

show data

{
  "query": "tremor",
  "count": 1,
  "matches": [
    {
      "pt": "Immune effector cell-associated neurotoxicity syndrome",
      "soc": "Nervous system disorders",
      "synonyms": [
        "icans",
        "neurotoxicity",
        "neurologic toxicity",
        "confusion with tremor",
        "encephalopathy",
        "ice score drop"
      ]
    }
  ]
}

↳ meddra_lookup result

show data

{
  "query": "neurotoxicity",
  "count": 1,
  "matches": [
    {
      "pt": "Immune effector cell-associated neurotoxicity syndrome",
      "soc": "Nervous system disorders",
      "synonyms": [
        "icans",
        "neurotoxicity",
        "neurologic toxicity",
        "confusion with tremor",
        "encephalopathy",
        "ice score drop"
      ]
    }
  ]
}

Agent · turn 3

Let me confirm the rigors/chills coding with an alternative term.

⚙ calls meddra_lookup(term=chills)

↳ meddra_lookup result

show data

{
  "query": "chills",
  "count": 0,
  "matches": []
}

Agent · turn 4

No specific PT for rigors/chills in this teaching dictionary; clinically they are constituent symptoms of the CRS event and are subsumed under that diagnosis rather than coded separately.

ICSR-001 — AE Coding, Seriousness & Causality Assessment

Patient: 64M, ES-SCLC (2nd line), former smoker. Study drug: Tarlatamab (DLL3 T-cell engager / BiTE). Concomitant: dexamethasone premed, ondansetron.

1. MedDRA Coding

The case is best coded as two clinical syndromes (the diagnoses), with the individual symptoms rolled into them per the convention of coding to the reported diagnosis when one is provided.

Event (as reported)	MedDRA PT	SOC
Fever 39.2 °C + rigors + hypotension, graded as CRS	Cytokine release syndrome	Immune system disorders
Day-2 confusion + coarse tremor + ICE-score drop, called neurotoxicity	Immune effector cell-associated neurotoxicity syndrome (ICANS)	Nervous system disorders

Coding notes:
- The clinician gave unifying diagnoses ("cytokine release syndrome", "neurotoxicity"). Per ICH coding convention, when a diagnosis is reported you code the diagnosis rather than each component sign/symptom. So pyrexia (Pyrexia, General disorders), hypotension (Hypotension, Vascular disorders) and rigors are constituents of CRS; confusion and tremor are constituents of ICANS.
- The synonym mapping confirms "confusion with tremor," "ICE score drop," and "neurotoxicity" all resolve to the ICANS PT.
- "Febrile neutropenia" was deliberately not used — there is no documented neutropenia in this case, so the fever codes to Pyrexia (within CRS), not Febrile neutropenia.
- Rigors/chills has no standalone PT in this dictionary; clinically subsumed within CRS — no information lost.

2. Seriousness Assessment

Apply ICH E2A serious criteria (death / life-threatening / hospitalization or prolongation / disability / congenital anomaly / other medically important).

Event	Serious?	Criterion met
Cytokine release syndrome	SERIOUS	Caused hospitalization (admitted). Also arguably medically important/potentially life-threatening (hypotension 88/54 requiring IV fluids, treated with tocilizumab).
ICANS	SERIOUS	Occurred during the hospitalization; neurologic toxicity with encephalopathy is a medically important event.

Both events are serious — primarily on the hospitalization criterion. Note both ultimately resolved within ~48h with treatment, so they were not fatal or persistently disabling, but resolution does not downgrade seriousness once a serious criterion was met.

3. Causality Assessment (drug = Tarlatamab)

Event 1 — Cytokine release syndrome → RELATED (Certain/Probable)

Temporal plausibility: onset ~8 h after the first step-up dose — the textbook window for T-cell-engager CRS (label note: "typically occur within days of the first/step-up doses").
Biological plausibility / labeled: CRS is a boxed warning and a very common, on-target expected reaction of DLL3 BiTEs.
Dechallenge/rechallenge: Responded to tocilizumab + steroids (mechanism-specific therapy); on rechallenge at next cycle (with premedication) had only mild recurrence — a positive rechallenge strongly supports causality.
Alternative cause excluded: infectious workup negative, so sepsis is not the explanation for the fever/hypotension.
Conclusion: Highest causality tier. Drug-related.

Event 2 — ICANS → RELATED (Probable)

Temporal plausibility: day 2, immediately following the CRS — the expected sequence (ICANS commonly follows CRS with T-cell engagers).
Biological plausibility / labeled: ICANS is explicitly in the boxed warning and labeled for this class.
Confounders considered: dexamethasone/ondansetron do not typically cause this picture; no CNS infection or other cause identified; no documented metabolic/structural alternative. Objective ICE-score drop supports a genuine neurotoxic process rather than nonspecific delirium.
Dechallenge: resolved with steroids over 48 h, consistent with drug-induced ICANS.
Conclusion: Probable/related. (Slightly less than "certain" only because individual ICANS components are less specific than the CRS syndrome and there was no clean isolated rechallenge of ICANS, but the constellation is characteristic.)

4. Summary Line for the ICSR

64M on tarlatamab (DLL3 BiTE), first step-up dose. Cytokine release syndrome (Immune system disorders) and ICANS (Nervous system disorders), both serious (hospitalization), both assessed related to study drug — CRS certain/probable (textbook timing, boxed-warning on-target effect, negative infection workup, positive rechallenge), ICANS probable (expected post-CRS sequence, labeled, dechallenge with steroids, no alternative cause). Both resolved within ~48 h.

Two flags worth raising to the medical reviewer:
1. Both are expected/labeled (boxed warning) reactions — relevant for expedited-reporting expectedness determination (serious + related, but expected).
2. The mild rechallenge recurrence at the next cycle is itself reportable follow-up information supporting causality.

Would you like me to format this as a structured ICSR causality narrative, or proceed to code the next case?

Event (as narrated)	Expected PT	Expected SOC	Seriousness (ICH E2A)	Causality (WHO-UMC) + rationale
fever with low blood pressure (CRS)	Cytokine release syndrome	Immune system disorders	Serious — Hospitalization (and medically important)	Probable — Onset hours after the first step-up dose (tight temporal link), CRS is a labeled/boxed on-target effect of T-cell engagers, no infection found (no alternative cause), positive dechallenge with tocilizumab/steroids and only mild recurrence on rechallenge with premedication. Strong case; 'Certain' is defensible if rechallenge is weighted heavily.
confusion with tremor (neurotoxicity)	Immune effector cell-associated neurotoxicity syndrome	Nervous system disorders	Serious — Hospitalization (and medically important)	Probable — Onset day 2 after dosing, ICANS-type neurotoxicity is a labeled/boxed class effect, resolved with steroids (positive dechallenge), no metabolic or structural alternative identified.
OVERALL CASE	—	—	Serious — Hospitalization / initially life-threatening (CRS with hypotension)	Case-level ICH-E2A determination

Adverse-Event Coding & Causality — agent trajectory for expert review

Query

Trajectory

ICSR-001 — AE Coding, Seriousness & Causality Assessment

1. MedDRA Coding

2. Seriousness Assessment

3. Causality Assessment (drug = Tarlatamab)

Event 1 — Cytokine release syndrome → RELATED (Certain/Probable)

Event 2 — ICANS → RELATED (Probable)

4. Summary Line for the ICSR

Final output

ICSR-001 — AE Coding, Seriousness & Causality Assessment

1. MedDRA Coding

2. Seriousness Assessment

3. Causality Assessment (drug = Tarlatamab)

Event 1 — Cytokine release syndrome → RELATED (Certain/Probable)

Event 2 — ICANS → RELATED (Probable)

4. Summary Line for the ICSR

Expert grading